NasdaqGM:ARTVBiotechs
Artiva Biotherapeutics (ARTV): Evaluating Valuation After FDA Fast Track Milestone for Refractory Rheumatoid Arthritis Therapy
Artiva Biotherapeutics (ARTV) recently secured Fast Track Designation from the U.S. FDA for its AlloNK therapy in combination with rituximab, a treatment aimed at refractory rheumatoid arthritis. This recognition has captured significant market attention.
See our latest analysis for Artiva Biotherapeutics.
Artiva Biotherapeutics shares rocketed after news of the FDA Fast Track Designation, notching a remarkable 108.7% 1-month share price return and delivering 132.9% over the past 90 days...